Pramodini Medicare Limited
NSE: PRAMODINIHealthcare Service Provider
Share price
₹116.50
+1.84% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
66
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹252 Cr
P/E ratio
14.8
P/B ratio
—
ROCE
41.8%
ROE
38.6%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 22.4% a year against a sector median of 13.1% — 9.3 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 0.4 times its growth rate, on earnings growth of 42%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Pramodini Medicare Limited — this one | 42%/yr | 14.8× | ₹0.35 |
| Vijaya Diagnostic Centre Limited | 24%/yr | 76.5× | ₹3.2 |
| Metropolis Healthcare Limited | 11%/yr | 51.6× | ₹4.7 |
| Thyrocare Technologies Limited | 36%/yr | 44.3× | ₹1.2 |
| Nephrocare Health Services Limited | 103%/yr | 73.7× | — |
| Krsnaa Diagnostics Limited | 18%/yr | 17.5× | ₹0.97 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Healthcare Service Provider), it ranks 2 of 12 on returns, 4 of 11 on growth, 1 of 12 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 41.8% on capital, ahead of 83% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹81 crore of cash from the business, spent ₹64 crore on plant and equipment, and returned ₹1 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 5 years, about 176 arrived as cash — well above the profit, more than depreciation and interest account for, so do not count on it repeating. Its cash comes back more slowly than it used to: it went from being paid 66 days before it paid its own suppliers to waiting 2 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
6 of 7 checks clear · 86%
Latest result
What the last results showed. Whether management kept its word is in Pro.
Results are expected soon.
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹252 Cr
- Prev close
- ₹116.50
- 52w High
- ₹137
- 52w Low
- ₹110
- Enterprise value
- ₹264 Cr
- Beta
- —
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 18.1%
- PEG ratio
- 0.3
- P/E ratio
- 14.8
- P/B ratio
- —
- EV / EBITDA
- 8.7
- Industry P/E
- 44.1
- ROCE
- 41.8%
- ROCE 5y average
- 35.0%
- ROE
- 38.6%
- Debt / Equity
- 0.3
- Interest coverage
- 24.0
- Dividend yield
- 0.0%
- ROE 3y average
- 36.0%
- ROE last year
- 39.0%
Annual P&L
- Annual revenue
- ₹62 Cr
- Annual profit
- ₹17 Cr
- Operating margin
- 50.0%
- Net profit margin
- 27.4%
- EBITDA margin
- 50.0%
- Sales growth 3y
- 26.0%
- Sales growth 5y
- —
- Profit growth 3y
- 42.0%
- Profit growth 5y
- —
- EPS
- ₹10.4
- Sales growth TTM
- 63.0%
- Profit growth TTM
- 58.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- —
- Profit latest quarter
- —
- YoY quarterly sales growth
- —
- YoY quarterly profit growth
- —
- OPM latest quarter
- —
Balance Sheet
- Book Value
- ₹24.0
- Face Value
- ₹10.0
- Total debt
- ₹18 Cr
- Total cash
- ₹6 Cr
- Borrowings
- ₹18 Cr
- Reserves / Equity
- 2.1
Cash Flow
- Operating cash flow
- ₹25 Cr
- Free cash flow
- -₹4 Cr
- FCF yield
- -2.0%
- Net cash flow
- ₹0 Cr
Shareholding
- Promoter holding
- 62.6%
- FII holding
- 2.8%
- DII holding
- 8.6%
- Public holding
- 25.9%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | 1,942.70 | 58.0 | 32,608 | 0.70 | 170.5 | 28.0 | 797.7 | 19.1 | 28.0 |
| Vijaya Diagnost. | 1,459.25 | 80.2 | 15,030 | 0.14 | 53.1 | 37.6 | 231.0 | 22.8 | 20.5 |
| Metropolis Healt | 542.35 | 54.1 | 11,251 | 0.36 | 56.9 | 25.8 | 450.2 | 16.6 | 17.8 |
| Thyrocare Tech. | 521.90 | 46.0 | 8,307 | 1.74 | 51.3 | 34.1 | 240.0 | 24.3 | 35.4 |
| Nephrocare Health Services | 636.20 | 75.2 | 6,398 | 0.00 | 32.0 | 34.9 | 281.8 | 23.7 | 15.3 |
| Krsnaa Diagnost. | 549.00 | 18.0 | 1,781 | 0.36 | 15.8 | -19.1 | 210.7 | 19.9 | 12.7 |
| Suraksha Diagno. | 327.45 | 47.6 | 1,705 | 0.15 | 12.9 | 38.4 | 87.7 | 20.8 | 17.3 |
| Pramodini Medicare | 116.90 | 14.8 | 258 | 0.00 | 41.8 | ||||
| Median | 327.45 | 34.3 | 1,104 | 0.00 | 11.0 | 28.0 | 95.2 | 19.1 | 20.5 |
Competes with: Dr. Lal Path Labs Ltd., Krsnaa Diagnostics Limited, Metropolis Healthcare Limited, Nephrocare Health Services Limited, Shiprocket Limited, Suraksha Diagnostic Limited, Thyrocare Technologies Limited, Vijaya Diagnostic Centre Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
This company does not publish this table.
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 25 | 31 | 35 | 38 | 62 |
| Expenses | 13 | 16 | 20 | 17 | 31 |
| Operating Profit | 12 | 15 | 16 | 21 | 31 |
| OPM % | 49 | 49 | 44 | 55 | 50 |
| Other Income | 0 | 0 | 1 | 0 | 1 |
| Interest | 2 | 2 | 2 | 1 | 1 |
| Depreciation | 4 | 5 | 4 | 4 | 7 |
| Profit before tax | 7 | 8 | 10 | 16 | 23 |
| Tax % | 29 | 27 | 29 | 29 | 25 |
| Net Profit | 5 | 6 | 7 | 11 | 17 |
| EPS in Rs | 4.92 | 4.76 | 5.40 | 86 | 10 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- —
- 3 years
- 26%
- TTM
- 63%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- 42%
- TTM
- 58%
Return on equity
- 10 years
- —
- 5 years
- 38%
- 3 years
- 36%
- Last year
- 39%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 17 |
| Reserves | 10 | 18 | 23 | 34 | 36 |
| Borrowings | 25 | 21 | 12 | 11 | 18 |
| Other Liabilities | 6 | 9 | 12 | 10 | 23 |
| Total Liabilities | 41 | 50 | 49 | 56 | 94 |
| Fixed Assets | 26 | 22 | 16 | 22 | 44 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 15 | 27 | 33 | 35 | 49 |
| Total Assets | 41 | 50 | 49 | 56 | 94 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from Operating Activity | 12 | 12 | 10 | 22 | 25 |
| Cash from Investing Activity | -12 | -12 | -1 | -15 | -31 |
| Cash from Financing Activity | 3 | 3 | -11 | -2 | 6 |
| Net Cash Flow | 3 | 3 | -2 | 5 | 0 |
| Free Cash Flow | -0 | -0 | 9 | 12 | -4 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 109 | 172 | 186 | 107 | 102 |
| Cash Conversion Cycle | 109 | 172 | 186 | 107 | 102 |
| Working Capital Days | -66 | -36 | 16 | -0 | 2 |
| ROCE % | 27 | 30 | 41 | 42 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
No industry numbers filed for this company yet.
News
News and filings about Pramodini Medicare Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Healthcare Service Provider
- Classification
- Healthcare › Healthcare Service Provider
- ISIN
- INE2JG601017
News impact
Big market events that reach Pramodini Medicare Limited, and how the effect spreads.
No recent market events reach this company.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 16 Sep 2026 | NIRAJ RAJNIKANT SHAH | SELL | 3,13,200 | ₹114.95 |
| 19 Aug 2026 | NIRAJ RAJNIKANT SHAH | BUY | 9,46,800 | ₹120.06 |
| 19 Aug 2026 | BEACON STONE CAPITAL VCC - BEACON STONE I | SELL | 2,31,600 | ₹119.32 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
No documents on record yet.
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.